Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)
- Conditions
- Neoplasms, Unknown Primary
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2012-08-15
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01202786
- Locations
- 🇮🇱
Ha'emek Medical Center, Afula, Israel
🇮🇱Rabin Medical Center, Petah Tikva, Israel
🇮🇱Soroka Medical Center, Beer-Sheva, Israel
A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy
- Conditions
- Female ContraceptionContraception
- Interventions
- Drug: DR-102
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 2858
- Registration Number
- NCT01178125
- Locations
- 🇮🇱
Teva Investigational Site 80102, Tel-Aviv, Israel
🇮🇱Teva Investigational Site 80101, Modi'in, Israel
🇮🇱Teva Investigational Site 80106, Tel-Aviv, Israel
Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- Drug: Beclomethasone dipropionate hydrofluoroalkane HFA Nasal AerosolDrug: Placebo Nasal Aerosol
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 474
- Registration Number
- NCT01134705
- Locations
- 🇺🇸
Teva Clinical Study Site, Bellevue, Washington, United States
Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- Drug: Placebo Nasal AerosolDrug: Placebo Prednisone Capsules
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2012-07-04
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 107
- Registration Number
- NCT01133626
- Locations
- 🇺🇸
Teva Clinical Study Site, San Antonio, Texas, United States
Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel
- Conditions
- Chemotherapy-induced Neutropenia
- Interventions
- Biological: PegfilgrastimBiological: NeugraninDrug: Chemotherapy
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 381
- Registration Number
- NCT01126190
- Locations
- 🇧🇬
Teva Investigational Site 3506, Sofia District, Bulgaria
🇧🇬Teva Investigational Site 3503, Stara Zagora, Bulgaria
🇷🇴Teva Investigational Site 4011, Cluj-Napoca, Romania
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT01088984
- Locations
- 🇺🇸
Teva Investigational Site 15, New York, New York, United States
🇺🇸Teva Investigational Site 17, Orange, California, United States
🇺🇸Teva Investigational Site 12, San Diego, California, United States
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis
- Conditions
- Lupus Nephritis
- Interventions
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT01085097
- Locations
- 🇺🇸
Teva Investigational Site 1022, Lake Success, New York, United States
🇬🇧Teva Investigational Site 3412, Dudley, United Kingdom
🇨🇦Teva Investigational Site 1114, Winnipeg, Manitoba, Canada
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT01085084
- Locations
- 🇺🇸
Teva Investigational Site 1366, Charleston, South Carolina, United States
🇺🇸Teva Investigational Site 1369, Bronx, New York, United States
🇨🇦Teva Investigational Site 1142, Montreal, Quebec, Canada
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-02-11
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1404
- Registration Number
- NCT01067521
- Locations
- 🇨🇿
Teva Investigational Site 5432, Prague 10, Czechia
🇺🇸Teva Investigational Site 1326, Fullerton, California, United States
🇺🇸Teva Investigational Site 1349, Columbus, Ohio, United States
A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2010-01-29
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT01058863
- Locations
- 🇺🇸
Teva Clinical Study Site, Portland, Oregon, United States